|Day's Range||0.48 - 0.51|
|52 Week Range||0.19 - 1.13|
|PE Ratio (TTM)||-4.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By John Vandermosten, CFA OTC:ONCYF Public Offering of Shares Strengthens Balance Sheet In late May, 2017, Oncolytics Biotech, Inc. (OTC:ONCYF) announced and priced 16.4 million units at CAD$0.70 per share ...
Toronto, Ontario--(Newsfile Corp. - June 1, 2017) - The following issues have been halted by IIROC: Company: Oncolytics Biotech Inc. Common share purchase warrants TSX Symbol: ONC.WT ...
By John Vandermosten, CFA OTC:ONCYF On May 8th, Oncolytics Biotech, Inc. (OTC:ONCYF) announced that the FDA had granted Fast Track status to REOLYSIN for the treatment of metastatic breast cancer. Fast ...